beta-thalassemia microelectronic chip: A fast and accurate method for mutation detection

Department of Medicine , Thomas Jefferson University, Filadelfia, Pennsylvania, United States
Clinical Chemistry (Impact Factor: 7.77). 02/2004; 50(1):73-9. DOI: 10.1373/clinchem.2003.023077
Source: PubMed

ABSTRACT beta-Thalassemia is one of the most common genetic diseases in humans. We developed an automated electronic microchip for fast and reliable detection of the nine most frequent mutations accounting for >95% of the beta-thalassemia alleles in the Mediterranean area.
We developed a microchip-based assay to identify the nine most frequent mutations (cd39C>T, IVS1-110G>A, IVS1-1G>A, IVS1-6T>C, IVS2-745C>G, cd6delA, -87C>G, IVS2-1G>A, and cd8delAA) by use of the Nanogen Workstation. The biotinylated amplicon was electronically addressed on the chip to selected pads, where it remained embedded through interaction with streptavidin in the permeation layer. The DNA at each test site was then hybridized to a mixture of fluorescently labeled wild-type or mutant probes.
Assays conditions were established based on the analysis of 700 DNA samples from compound heterozygotes or homozygotes for the nine mutations. The assays were blindly validated on 250 DNA samples previously genotyped by other methods, with complete concordance of results. Alternative multiplexed formats were explored: the combination of multiplex PCR with multiple addressing and/or hybridization allowed analysis of all nine mutations in the same sample on one test site of the chip.
The open flexible platform can be designed by the user according to the local prevalence of mutations in each geographic area and can be rapidly extended to include the remaining mutations causing beta-thalassemia in other regions of the world.

  • Source
    01/2012; DOI:10.4172/2155-6210.1000123
  • [Show abstract] [Hide abstract]
    ABSTRACT: Bio-microelectromechanical systems (BioMEMS) have myriad applications that range from surgical tools to gene-sequencing chips. A full review of all its applications is beyond the scope of the present paper. This study is a comprehensive overview of applications of BioMEMS in the diagnosis of diseases, scientific research based on cell biology, and therapy or treatment of medical conditions. This is a review, from a biologist’s perspective, of the current foci of research in these areas. The design and working principles applied are described, and progress made thus far is traced. Some of the design concepts that are likely to play an important role in future applications are also identified. Additionally, the major challenges to be overcome in order for BioMEMS technology to meet its full potential have been described.
    12/2013; 3(4). DOI:10.1007/s12668-013-0112-7
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: β-Thalassemias and abnormal hemoglobin variants are among the most common hereditary abnormalities in humans. Molecular characterization of the causative genetic variants is an essential part of the diagnostic process. In geographic areas with high hemoglobinopathy prevalence, such as the Mediterranean region, a limited number of genetic variants are responsible for the majority of hemoglobinopathy cases. Developing reliable, rapid and cost-effective mutation-specific molecular diagnostic assays targeting particular populations greatly facilitates routine hemoglobinopathy investigations. We developed a one-tube single-nucleotide primer extension assay for the detection of eight common Mediterranean β-thalassemia mutations: Codon 5 (-CT); CCT(Pro)->C-, Codon 6 (-A); GAG(Glu)->G-G, Codon 8 (-AA); AAG(Lys)->-G, IVS-I-1 (G->A), IVS-I-6 (T->C), IVS-I-110 (G->A), Codon 39 (C->T), and IVS-II-745 (C->G), as well as the hemoglobin S variant beta 6(A3) Glu>Val. We validated the new assay using previously genotyped samples obtaining 100% agreement between independent genotyping methods. Our approach, applicable in a range of Mediterranean countries, offers a combination of high accuracy and rapidity exploiting standard techniques and widely available equipment. It can be further adapted to particular populations by including/excluding assayed mutations. We facilitate future modifications by providing detailed information on assay design.
    PLoS ONE 10/2012; 7(10):e48167. DOI:10.1371/journal.pone.0048167 · 3.53 Impact Factor

Full-text (2 Sources)

Available from
Jan 15, 2015